Ideaya Biosciences Inc Dossier
Qualitative Analysis
Business overview
IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for patient populations selected using molecular diagnostics. The company's scientific approach centers on its proprietary synthetic lethality platform, which targets biological mechanisms where the simultaneous loss of two specific genes results in cancer cell death while sparing normal cells. IDEAYA's deep pipeline includes several potentially first-in-class or best-in-class small molecule inhibitors and antibody-drug conjugates (ADCs). Key clinical programs include darovasertib (a PKC inhibitor being developed for uveal melanoma), IDE397 (a MAT2A inhibitor), IDE892 (an MTA-cooperative PRMT5 inhibitor), and IDE849 (a DLL3 TOP1 ADC).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing darovasertib across the entire uveal melanoma disease continuum, including registrational trials in metastatic (OptimUM-02), neoadjuvant (OptimUM-10), and adjuvant (OptimUM-11) settings.
Expected impact: Establishes a comprehensive franchise in uveal melanoma, addressing high unmet medical needs where no standard FDA-approved therapies exist.
Developing antibody-drug conjugate (ADC) and DNA damage response (DDR) combinations, highlighted by IDE849 (DLL3 TOP1 ADC) and IDE034 (B7H3/PTK7 bispecific TOP1 ADC).
Expected impact: Expands the clinical pipeline beyond small molecules into high-potential biologic modalities targeting solid tumors.
Advancing MAT2A inhibitor IDE397 and PRMT5 inhibitor IDE892 as monotherapies and in rational combinations for MTAP-deleted solid tumors.
Expected impact: Targets a large genetically-defined patient population in lung, pancreatic, and bladder cancers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Servier holds exclusive rights to develop and commercialize darovasertib outside the United States, while IDEAYA retains full U.S. rights.
Terms: IDEAYA received a $210 million upfront payment in August 2025, and is eligible for up to $320 million in regulatory and commercial milestones, plus tiered double-digit royalties on ex-U.S. net sales. Servier also reimburses clinical development costs.
Focuses on the MAT2A program (IDE397). In December 2025, GSK notified IDEAYA of its decision to terminate the Werner Helicase (IDE275) and Pol Theta (IDE705) portions of the agreement, returning full global rights for those programs to IDEAYA in early 2026.
Terms: For the ongoing MAT2A program, the partnership includes a 50/50 U.S. profit share, ex-U.S. royalties, and a 20% global development cost share for IDEAYA.
IDEAYA acquired exclusive worldwide rights (excluding Greater China) to develop and commercialize IDE849, a DLL3-targeting TOP1 ADC.
Terms: IDEAYA paid an upfront licensing fee of $75 million in December 2024, with Hengrui eligible for subsequent development, regulatory, and sales milestones.
Evaluating IDEAYA's PRMT5 inhibitor IDE892 in combination with Roche's RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.
Terms: Clinical trial collaboration and supply agreement terms.